What is the value of treatment for individual cancer patients?

My last blog on the costs of drugs for the treatment of myeloma raised a number of issues for discussion, none more so than the heartfelt comment by Robert Fowler, who communicated to us his concerns about costs and the impact those costs may have on insurance for his fellow employees. Questions were also raised about the applicability of the “Value Framework” proposed by the American Society of Clinical Oncology (ASCO) to the assessment of myeloma.